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Abstract
The Thopaz+ portable digital system was evaluated by the Medical Technologies Advisory Committee (MTAC) of the 
National Institute for Health and Care Excellence (NICE). The manufacturer, Medela, submitted a case for the adoption of 
Thopaz+ that was critiqued by Cedar, on behalf of NICE. Due to a lack of clinical evidence submitted by the manufacturer, 
Cedar carried out its own literature search. Clinical evidence showed that the use of Thopaz+ led to shorter drainage times, 
a shorter hospital stay, lower rates of chest drain re-insertion and higher patient satisfaction compared to conventional chest 
drainage when used in patients following pulmonary resection. One comparative study of the use of Thopaz+ in patients with 
spontaneous pneumothorax was identified and showed shorter drainage times and a shorter length of hospital stay compared 
to conventional drainage. No economic evidence was submitted by the manufacturer, but a simple decision tree model was 
included. The model was improved by Cedar and showed a cost saving of £111.33 per patient when Thopaz+ was used instead 
of conventional chest drainage in patients following pulmonary resection. Cedar also carried out a sub-group analysis of the 
use of Thopaz+ instead of conventional drainage in patients with pneumothorax where a cost saving of £550.90 was observed. 
The main cost driver for the model and sub-group analysis was length of stay. The sub-group analysis was based on a single 
comparative study. However, the MTAC received details of an unpublished audit of Thopaz+ which confirmed its efficacy in 
treating patients with pneumothorax. Thopaz+ received a positive recommendation in Medical Technologies Guidance 37.
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Key Points for Decision Makers 
Clinical evidence for Thopaz+ showed shorter drainage 
times and length of hospital stay, lower rates of chest drain 
re-insertion and higher rates of patient satisfaction when 
used in patients following pulmonary resection compared to 
conventional chest drainage. One comparative study of the 
use of Thopaz+ in patients with spontaneous pneumotho-
rax was identified and showed shorter drainage times and 
length of hospital stay compared to conventional drainage.
The use of Thopaz+ in patients following pulmonary 
resection and patients with pneumothorax led to cost sav-
ings compared to conventional drainage. The main driver 
for cost savings was a reduction in length of hospital stay.
1 Introduction
The Medical Technologies Evaluation Programme (MTEP) 
of the National Institute for Health and Care Excellence 
(NICE) evaluates innovative or new medical technologies. 
The programme provides support for National Health Ser-
vice (NHS) technology adoption and generates guidance 
on diagnostic technologies and medical devices [1].
The process of completing these evaluations, known 
as Medical Technologies Guidance (MTG), has previ-
ously been described in detail [2]. Briefly, technologies 
are selected based upon company notifications on their 
medical device or technology; those selected have a scope 
published by NICE and this is followed by a submission by 
the company. The submission contains both clinical and 
economic evidence in order to make a case for adoption 
of the technology. External assessment centres review and 
critique the manufacturer’s submission. The results of the 
review and critique are presented in an assessment report. 
The report is used, in addition to the manufacturer’s sub-
mission, by the Medical Technologies Advisory Commit-
tee (MTAC) during its decision-making process.
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This paper reports on how Cedar’s assessment report 
was used to inform MTG on the Thopaz+ portable digital 
system for managing chest drains. Cedar is a healthcare 
technology research centre formed through collaboration 
between Cardiff and Vale University Health Board and 
Cardiff University, and was responsible for producing the 
assessment report. Thopaz+ chest drain management sys-
tems are manufactured by Medela. This paper is part of 
a series that provides an insight into the development of 
NICE MTG [2].
2  Background to the Condition 
and Technology
Chest drains are required for the treatment of a number of 
procedures/conditions that affect the thoracic cavity. This 
includes, but is not restricted to, chest drainage following 
pulmonary resection and pneumothorax. In 2016–2017 
there were 32,317 chest drain insertions of the pleural 
cavity, 10,821 drainages of the pleural cavity and 7336 
instances of chest tubes of the pleural cavity requiring 
attention in England [3].
The insertion of chest drains has been recommended by 
NICE in their guideline for major trauma [4]. However, no 
previous guidance on chest drain management has been 
issued by NICE. The British Thoracic Society (BTS) has 
previously published guidelines on pleural disease [5]. The 
guidelines include recommendations on the use of chest 
drains including details on chest drain insertion, image 
guidance, aseptic technique, securing the drain, the drain-
age system used, and management of a chest drain. The 
guidelines do not specify the drainage system to be used 
for the chest drain; however, they do recommend that the 
drainage system should include a valve mechanism to pre-
vent fluid or air from entering the pleural cavity.
A number of chest drain management systems exist. 
Many of these are simple in design and consist of a closed 
underwater seal bottle, which can be connected to suction if 
deemed appropriate. The underwater seal enables a visual 
check of air leak through the presence/absence of bubbles. 
The Thopaz+ chest drain management differs from more 
traditional drain management systems by using digital algo-
rithms to monitor fluid drainage and air leakage in order to 
function. The device is able to maintain negative pressure 
and continuously monitor air leak. In addition, the device 
is portable and alerts users if safety issues, such as blocked 
tubing, arise. The manufacturer’s submission contained a 
number of claimed benefits to the patients and included: 
reduced chest tube duration, reduced length of hospital stay, 
reduced rates of patient complications and higher patient 
satisfaction. The manufacturer claimed healthcare system 
benefits including: reduced hospital costs, increased con-
venience for doctors and nursing staff, improved chest drain 
management and better prediction of patient outcomes.
3  Decision Problem (Scope)
The manufacturer must define and follow a decision problem 
in order to focus their submission. The decision problem is 
presented in a PICO (population, intervention, comparator, 
outcomes) table. The PICO table generated by the manu-
facturer was consistent with the final scope which was pub-
lished by NICE in May 2017 [6].
3.1  Population
For a population in their decision problem, the manufacturer 
identified “All people requiring a chest drain”.
3.2  Intervention
The manufacturer identified Thopaz+ as the intervention. 
However, at the time of their submission there was no pub-
lished evidence for the Thopaz+ device. All available evi-
dence was for the company’s earlier device, Thopaz. How-
ever, following discussions with the manufacturer, Cedar 
confirmed that the main method of action of the device 
has not changed so evidence for Thopaz is transferable and 
applicable to Thopaz+.
3.3  Comparator
The decision problem included the following comparators: 
underwater seal drains, chest drains involving a flutter valve 
and any other recognised mechanism or valve.
3.4  Outcomes
There were a number of outcomes listed by the manufac-
turer in their decision problem to provide evidence for their 
submitted claimed benefits. Clinical outcomes included 
duration of chest drain placement, incidence of chest drain 
re-insertion, fluid loss measurement, length of hospital stay, 
rate of complications and device-related adverse events and 
staff time. Patient satisfaction (including measures of patient 
discomfort) was the only patient-related outcome included 
by the company. The outcomes included by the manufacturer 
were used to assess their claimed benefits. From a healthcare 
perspective, a reduced length of hospital stay, reduced rate 
of complications and fewer adverse events would lead to 
reduced hospital costs.
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4  Review of Clinical Effectiveness Evidence
4.1  Manufacturer’s Review of Clinical Effectiveness 
Evidence
Evidence submitted by the manufacturer aimed to match 
the scope [6]. A total of three studies were submitted by the 
manufacturer for consideration. One of the submitted stud-
ies was a randomised controlled trial (RCT) comparing the 
use of Thopaz to traditional “water-seal” suction drainage in 
patients following pulmonary resection [7]. The manufacturer 
also included one non-comparative study of the use of Thopaz 
in patients following pulmonary resection or lung biopsy [8], 
which was excluded by Cedar due to being out of scope. The 
remaining study was a non-comparative evaluation of the use 
of Thopaz in patients with pneumothorax [9]. The manufac-
turer included only studies that were freely available. Adverse 
events were searched for by the addition of extra search terms 
to the manufacturer’s search strategy. No search for adverse 
events was carried out in the US Food and Drug Administra-
tion (FDA) Manufacturer and User Facility Device Experi-
ence (MAUDE) database. However, the manufacturer gave 
details of one adverse event reported through the Medicines 
and Healthcare products Regulatory Agency (MHRA).
4.2  Cedar’s Critique of Clinical Effectiveness 
Evidence
The manufacturer carried out basic literature searches in 
Medline, Medline In Process, Embase and The Cochrane 
Library. However, it was unclear if all Cochrane Library 
databases were searched. The manufacturer assessed a total 
of 15 records at full text for eligibility to the submission 
and excluded a total of 9 studies as they were conference 
abstracts with insufficient data. The manufacturer also 
excluded 3 studies as they were not available free of charge 
online. Cedar did not feel this was a valid reason to exclude 
these studies, but the 3 studies were subsequently excluded 
by Cedar as they were conference abstracts with insufficient 
data. The company submitted critical appraisal checklists 
for all their included studies, and used the appropriate forms 
for each study type. The checklists were adapted from the 
Centre for Reviews and Dissemination [10].
Due to the simple search strategy used by the manufac-
turer, Cedar felt it was likely that relevant studies were not 
identified. Therefore, Cedar carried out its own literature 
search and reported its results using Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) 
methodology [11] (Fig. 1). In total, Cedar identified 11 stud-
ies relevant to the scope of this assessment [12–22] in addi-
tion to the two studies identified by the manufacturer, and 
included by Cedar [7, 9] to give a total of 13 studies.
Of the 13 included studies, there were six RCTs [7, 12, 
14–16, 18], three observational comparative studies that 
used propensity matching for their analysis [20–22], three 
observational studies with no comparative element [9, 13, 
17] and one prospective comparative study [19]. The com-
parators in almost all of the RCTs and comparative obser-
vational studies were traditional analogue chest drainage 
systems that used wall-mounted suction. One of the RCTs 
used Thopaz at two different suction settings, and compared 
outcomes for these settings [12]. Eleven of the studies used 
the device in a patient population that had undergone pul-
monary resection [7, 12–14, 16–22]. Two studies used the 
device in a patient population with pneumothorax [9, 15]. 
A search of the FDA MAUDE database was not carried out 
by the manufacturer. Therefore, Cedar carried out its own 
search; in total, five adverse events were reported.
4.3  Cedar’s Conclusions on the Clinical Evidence
A total of 13 studies were included by Cedar and of these, 
2 were submitted by the company [7, 9]. In most of the 
included comparative studies of Thopaz and conventional/
analogue drainage, patients who underwent pulmonary 
resection who were treated postoperatively with Thopaz 
had a shorter duration of chest tube drainage and a shorter 
hospital stay. Only one study reported a non-significant 
longer hospital stay for Thopaz [18]. No studies reported a 
longer duration of chest tube drainage with Thopaz. Two of 
the identified studies presented results for Thopaz used in 
patients with pneumothorax, one of which was comparative 
[15]. The results of this paper showed that both the duration 
of drainage and length of hospital stay were significantly 
shorter when using Thopaz. A single included study com-
pared patient satisfaction between Thopaz and traditional 
drainage in patients undergoing pulmonary resection [7]. 
This study showed that patients treated with Thopaz had 
an improved ability to arise from bed, improved perceived 
system convenience, felt more comfortable being discharged 
home with the device if needed and fewer felt they would 
want to change the system compared with those treated 
with a traditional drainage device. The incidence of drain 
re-insertion was reported in 4 comparative papers where the 
incidence was non-significantly lower for Thopaz in 3 of 
these studies [14, 18, 22] than traditional drainage. No drain 
re-insertions were required for patients treated with Tho-
paz or traditional drainage in one paper [16]. Cedar found 
no quantitative, comparative evidence measuring staff time 
saved when using Thopaz.
The evidence identified by Cedar was mainly from 
patients treated with Thopaz postoperatively following 
pulmonary resection. Cedar identified two studies where 
Thopaz was used for treatment of pneumothorax, one of 
which was a comparative study. This limited conclusions 
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on the effectiveness of Thopaz in this patient group. The 
population identified in the scope was broad, but Cedar 
found no evidence for the use of Thopaz other than post-
operative use in patients undergoing pulmonary resection 
or for the treatment of pneumothorax. Cedar did not find 
comparative evidence on the use of Thopaz for fluid loss 
measurement, an outcome in the scope. One identified 
paper looked at the use of Thopaz in a paediatric cohort 
[13]. Although non-comparative, this study was included 
to provide evidence for use in children in line with the sub-
groups defined in the scope. Further evidence is required 
to draw any conclusions on the effectiveness of Thopaz+ 
other than in patients undergoing pulmonary resection. It 
is also worth noting that centres included in each study 
followed different procedures for chest drain manage-
ment. These are likely to affect the duration of chest tube 
drainage and in turn length of hospital stay. A summary 
of Cedar’s included studies has been presented (Table 1).
5  Economic Evidence
5.1  Manufacturer’s Economic Submission
The manufacturer’s economic submission did not identify 
published economic evidence. The manufacturer submitted 
a de-novo economic model that followed a simple decision 
tree structure with a single decision node for Thopaz+ 
or standard drainage with wall suction. Clinical data for 
model inputs were obtained from a study of the use of 
Thopaz in patients following pulmonary resection that the 
company submitted as part of their clinical evidence [7]. 
Fig. 1  PRISMA diagram showing Cedar’s literature search results for Thopaz+. PRISMA Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses
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Due to the choice of study, Cedar assumed the model was 
based on patients undergoing pulmonary resection. The 
manufacturer did not include data on patients with pneu-
mothorax in their analysis. The technology considered was 
Thopaz+ and the comparator was standard drainage with 
wall suction in line with the scope. In their model the man-
ufacturer made a key assumption that the cost of treatment 
with the comparator is zero, arguing that wall suction and 
all consumables are all readily available. The time horizon 
for the model was equal to the length of hospital stay.
Results of the manufacturer’s economic analysis gave a 
base-case cost of £1624.27 for Thopaz+ and £1659.83 for 
standard drainage with suction. The manufacturer there-
fore estimated that using Thopaz+ would save £35.56 per 
patient when used in place of standard drainage with suc-
tion over the length of their hospital stay.
5.2  Critique of Economic Evidence
The manufacturer’s submission did not contain any pub-
lished economic evidence for Cedar to critique. However, 
the manufacturer utilised data on chest tube drainage from 
a study they submitted as part of their clinical evidence 
[7]. The manufacturer chose not to carry out cost model-
ling based on the study they submitted for patients with 
pneumothorax [9]. Cedar believed that the company’s lit-
erature search for clinical evidence did not identify all 
available evidence on Thopaz. With a greater body of evi-
dence, parameters such as chest tube duration could have 
been altered to reflect results in the literature.
5.3  Critique of the De Novo Model
The manufacturer’s de novo model was a simple decision 
tree, but the manufacturer did not explicitly state which 
group of patients their economic model was based upon. 
Cedar assumed the model was based on patients undergo-
ing pulmonary resection due to the study used to provide 
inputs into the model [7]. The manufacturer assumed there 
were no costs for the comparator. Cedar disagreed with 
this approach. There are costs associated with conven-
tional drainage including the cost of the traditional device 
and its associated consumables. Including these costs 
would increase the cost saving of Thopaz+ in the submit-
ted model. The model included training costs by using an 
estimate of the time taken for training coupled with staff-
ing costs [23]. The company was highly conservative with 
their estimates of staffing costs, assuming that all phy-
sicians/surgeons were at consultant level and all nurses/
other healthcare staff were also at consultant level. Cedar 
felt that assuming all nurses/other healthcare staff were at 
consultant level was too conservative and increased the 
costs of Thopaz+. Not all of the available device pricing 
options were explored by the manufacturer. Deterministic 
sensitivity analysis carried out by the manufacturer did 
not take into account the difference in cost of rental for 
Thopaz+ and the different canister options available, in 
terms of canister size and whether or not the canister con-
tains a solidifying agent. Finally, the manufacturer did not 
use expert advisers to inform their economic model or 
submission.
Following its critique, Cedar made a number of changes 
to the submitted model. Studies identified by Cedar were 
used to calculate means for duration of chest tube placement, 
length of hospital stay when using Thopaz+ and length of 
hospital stay when using traditional drainage. Cedar con-
tacted expert advisers to determine a more robust figure for 
training costs. In addition, Cedar also included comparator 
costs, and calculated an incidence rate for chest drain re-
insertion and its associated cost. Cedar conducted a number 
of scenario analyses including: the use of a purchased Tho-
paz+ machine for postoperative use in patients following 
pulmonary resection, the use of a rented Thopaz+ device 
and the use of a purchased Thopaz+ device for pneumotho-
rax treatment.
Following its changes, Cedar’s base-case showed a sav-
ing of £111.34 per patient when a rented Thopaz+ device 
was used postoperatively following pulmonary resection 
instead of conventional drainage. If a purchased Thopaz+ 
device was used in this patient population then savings were 
increased to £124.76 per patient if used instead of conven-
tional drainage. If a rented or purchased Thopaz+ device 
was used for the treatment of pneumothorax instead of con-
ventional drainage, then £550.90 and £558.57 per patient 
could be saved, respectively. In the base-case and all sce-
narios the main cost driver was length of hospital stay.
6  NICE Guidance
6.1  Provisional Recommendations and Consultation
The evidence submitted by the company and Cedar’s critique 
of this evidence was presented to the MTAC who provided 
draft recommendations relating to Thopaz+ following their 
meeting in September 2017. These were as follows:
• The case for adopting Thopaz+ for managing chest drains 
is supported by the evidence. Thopaz+ can reduce drain-
age time and length of stay in hospital, and improves 
safety for people with chest drains. Its use may also 
improve clinical decision making through continuous, 
objective monitoring of air leaks and fluid loss.
 J. M. Evans et al.
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Thopaz+ Portable Digital System for Managing Chest Drains
• Thopaz+ should be considered for people who need 
chest drainage after pulmonary resection or because of a 
pneumothorax. The system can increase patient mobility 
because it is portable. Staff find it more convenient and 
easier to use than standard wall suction.
• Cost modelling indicates that Thopaz+ is cost saving 
compared with standard wall suction in people who need 
chest drainage after pulmonary resection. The estimated 
saving is £111.33 per patient over their stay in hospi-
tal. These savings are mainly achieved through reduced 
length of stay in hospital.
6.2  Final NICE Guidance
During the consultation, NICE received 8 consultation com-
ments from 4 consultees. The NICE guidance was updated 
to address a number of these comments. The recommen-
dations had minor updates to better define the comparator 
as a conventional chest drain. Consultees suggested the 
evidence for Thopaz+ in pneumothorax was limited. The 
committee also received comments from an expert describ-
ing an unpublished audit of Thopaz+ use which confirmed 
the recommendations for use in pneumothorax. The Com-
mittee decided not to update the recommendations on 
pneumothorax.
7  Key Challenges and Learning Points
Through a combination of a lack of identified clinical 
evidence and no economic evidence coupled with weak-
nesses and limitations in the manufacturer’s de novo 
economic model, Cedar was able to make a number of 
improvements. This included contacting clinical experts 
for advice on model inputs, the inclusion of comparator 
costs and modification of clinical parameters (e.g. length 
of hospital stay) based on published clinical evidence. In 
addition, Cedar carried out a number of scenario analyses 
to consider different procurement options and the use of 
Thopaz+ in the treatment of pneumothorax.
One of the key challenges faced by the MTAC was 
determining whether Cedar’s scenario analysis of the 
use of Thopaz+ for the treatment of pneumothorax was 
reliable. The length of stay model input for this scenario 
came from a single comparative study [15]. In response, a 
clinical expert was able to share audit data from their NHS 
hospital which showed that Thopaz+ showed similar clini-
cal advantages for patients following pulmonary resection 
and for the treatment of pneumothorax.
There was a lack of comparative evidence for the use 
of Thopaz+ in paediatric patients. Clinical experts noted 
that if the devices are available on wards they may be 
used safely for a range of patients. However, evidence for 
the use of Thopaz+ in a paediatric population is currently 
lacking.
8  Conclusion
Thopaz+ received a positive recommendation from NICE 
and should be considered for managing chest drains. 
Published evidence showed that Thopaz+ can reduce the 
duration of chest tube drainage and length of hospital 
stay. In its scenario analysis, Cedar showed that savings 
achieved using Thopaz+ instead of traditional drainage 
were greater for patients with pneumothorax than those 
achieved when using Thopaz+ postoperatively following 
pulmonary resection. Cedar highlighted uncertainty over 
the scenario analysis. However, audit data showed similar 
clinical advantages for the use of Thopaz+ in patients with 
pneumothorax and when used postoperatively following 
pulmonary resection.
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